Regulation of let-7 and its target oncogenes (Review)

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 955-960

  Wang, Xirui ^a   Cao, Lei ^a   Wang, Yingyi ^a   Wang, Xiefeng ^a   Liu, Ning ^a   You, Yongping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Let 7; MicroRNA; Regulation; Regulatory circuit

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN ENHANCER BINDING FACTOR 2; INTERLEUKIN ENHANCER BINDING FACTOR 3; MICRORNA; MICRORNA LET 7; MYC PROTEIN; RAS PROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CAENORHABDITIS ELEGANS; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 22Q; CPG ISLAND; DNA METHYLATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; REGULATORY MECHANISM; REVIEW; RNA BINDING; RNA SYNTHESIS;

EID: 84863262723     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.609     Document Type: Review

References (85)

1. Nilsen TW: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23: 243-249, 2007.
2. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T and Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293: 834-838, 2001.
3. Kim VN, Han J and Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139, 2009.
4. Carthew RW and Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell 136: 642-655, 2009.
5. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
6. Roush S and Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 18: 505-516, 2008.
7. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
8. Zhang HH, Wang XJ, Li GX, Yang E and Yang NM: Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 13: 2883-2888, 2007.
9. Akao Y, Nakagawa Y and Naoe T: Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906, 2006.
10. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762-9770, 2007.
11. Grosshans H, Johnson T, Reinert KL, Gerstein M and Slack FJ: The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell 8: 321-330, 2005.
12. Sokol NS, Xu P, Jan YN and Ambros V: Drosophila let-7 microRNA is required for remodeling of the neuromusculature during metamorphosis. Genes Dev 22: 1591-1596, 2008.
13. Caygill EE and Johnston LA: Temporal regulation of metamorphic processes in Drosophila by the let-7 and miR-125 heterochronic microRNAs. Curr Biol 18: 943-950, 2008.
14. Thomson JM, Parker J, Perou CM and Hammond SM: A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1: 47-53, 2004.
15. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414, 2007.
16. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
17. Chang TC and Mendell JT: MicroRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 8: 215-239, 2007.
18. Viswanathan SR, Daley GQ and Gregory RI: Selective blockade of microRNA processing by Lin28. Science 320: 97-100, 2008.
19. Newman MA, Thomson JM and Hammond SM: Lin-28 interaction with the let-7 precursor loop mediates regulated microRNA processing. RNA 14: 1539-1549, 2008.
20. Piskounova E, Viswanathan SR, Janas M, LaPierre RJ, Daley GQ, Sliz P and Gregory RI: Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem 283: 21310-21314, 2008.
21. Heo I, Joo C, Cho J, Ha M, Han J and Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell 32: 276-284, 2008.
22. Hagan JP, Piskounova E and Gregory RI: Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 16: 1021-1025, 2009.
23. Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J and Kim VN: TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138: 696-708, 2009.
24. Lehrbach NJ, Armisen J, Lightfoot HL, Murfitt KJ, Bugaut A, Balasubramanian S and Miska EA: LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in Caenorhabditis elegans. Nat Struct Mol Biol 16: 1016-1020, 2009.
25. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
26. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413, 2002.
27. Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 4: 351-358, 2003.
28. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-1429, 2007.
29. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA and Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
30. Yoshitomi T, Kawakami K, Enokida H, Chiyomaru T, Kagara I, Tatarano S, Yoshino H, Arimura H, Nishiyama K, Seki N and Nakagawa M: Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Oncol Rep 25: 1661-1668, 2011.
31. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sültmann H and Lyko F: The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67: 1419-1423, 2007.
32. Lu L, Katsaros D, de la Longrais IA, Sochirca O and Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67: 10117-10122, 2007.
33. Sakamoto S, Aoki K, Higuchi T, Todaka H, Morisawa K, Tamaki N, Hatano E, Fukushima A, Taniguchi T and Agata Y: The NF90-NF45 complex functions as a negative regulator in the micro RNA processing pathway. Mol Cell Biol 29: 3754-3769, 2009.
34. Iliopoulos D, Hirsch HA and Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706, 2009.
35. Boyerinas B, Park SM, Shomron N, Hedegaard MM, Vinther J, Andersen JS, Feig C, Xu J, Burge CB and Peter ME: Identification of let-7-regulated oncofetal genes. Cancer Res 68: 2587-2591, 2008.
36. Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN and Papamichail M: CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem 280: 20086-20093, 2005.
37. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, et al: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 106: 3384-3389, 2009.
38. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ and Rosner MR: Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 28: 347-358, 2009.
39. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
40. Hammell CM, Karp X and Ambros V: A feedback circuit involving let-7-family miRNAs and DAF-12 integrates environmental signals and developmental timing in Caenorhabditis elegans. Proc Natl Acad Sci USA 106: 18668-18673, 2009.
41. Diederichs S and Haber DA: Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131: 1097-1108, 2007.
42. Rybak A, Fuchs H, Hadian K, Smirnova L, Wulczyn EA, Michel G, Nitsch R, Krappmann D and Wulczyn FG: The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2. Nat Cell Biol 11: 1411-1420, 2009.
43. Forman JJ, Legesse-Miller A and Coller HA: A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA 105: 14879-14884, 2008.
44. Jakymiw A, Patel RS, Deming N, Bhattacharyya I, Shah P, Lamont RJ, Stewart CM, Cohen DM and Chan EK: Overexpression of dicer as a result of reduced let-7 microRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 49: 549-559, 2010.
45. Yonehara S, Ishii A and Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756, 1989.
46. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, et al: The CD95 receptor: apoptosis revisited. Cell 129: 447-450, 2007.
47. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G and Peter ME: CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23: 3175-3185, 2004.
48. Gordon N and Kleinerman ES: Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 23: 189-196, 2010.
49. Wang S, Tang Y, Cui H, Zhao X, Luo X, Pan W, Huang X and Shen N: Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun 12: 149-154, 2011.
50. Geng L, Zhu B, Dai BH, Sui CJ, Xu F, Kan T, Shen WF and Yang JM: A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem Biophys Res Commun 408: 494-499, 2011.
51. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X and Lu K: Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 70: 9765-9776, 2010.
52. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, et al: LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res 71: 3896-3903, 2011.
53. Chen AX, Yu KD, Fan L, Li JY, Yang C, Huang AJ and Shao ZM: Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. PLoS Genet 7: e1002259, 2011.
54. Lytle JR, Yario TA and Steitz JA: Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci USA 104: 9667-9672, 2007.
55. Nottrott S, Simard MJ and Richter JD: Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 13: 1108-1114, 2006.
56. Beilharz TH, Humphreys DT, Clancy JL, Thermann R, Martin DI, Hentze MW and Preiss T: MicroRNA-mediated messenger RNA deadenylation contributes to translational repression in mammalian cells. PLoS One 4: e6783, 2009.
57. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: Ras is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
58. Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ and Kelsey KT: KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69: 51-53, 2010.
59. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, et al: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540, 2008.
60. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, et al: A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12: 377-386, 2011.
61. Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, Park CK, Jung KH, Lee SK, Kim M and Roh JK: Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102: 19-24, 2010.
62. He XY, Chen JX, Zhang Z, Li CL, Peng QL and Peng HM: The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 136: 1023-1028, 2010.
63. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, Manfioletti G and Giancotti V: Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 574: 1-8, 2004.
64. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S: Increased expression of high mobility group A proteins in lung cancer. J Pathol 209: 206-212, 2006.
65. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46: 503-511, 2007.
66. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A and Atomi Y: An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89: 2104-2109, 2003.
67. Miyazawa J, Mitoro A, Kawashiri S, Chada KK and Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64: 2024-2029, 2004.
68. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S and Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 47: 56-63, 2008.
69. Borrmann L, Wilkening S and Bullerdiek J: The expression of HMGA genes is regulated by their 3'UTR. Oncogene 20: 4537-4541, 2001.
70. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K and Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 14: 2334-2340, 2008.
71. Shi G, Perle MA, Mittal K, Chen H, Zou X, Narita M, Hernando E, Lee P and Wei JJ: Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med 13: 3898-3905, 2009.
72. Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579, 2007.
73. Albihn A, Johnsen JI and Henriksson MA: Myc in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224, 2010.
74. Ruggero D: The role of Myc-induced protein synthesis in cancer. Cancer Res 69: 8839-8843, 2009.
75. Schultz J, Lorenz P, Gross G, Ibrahim S and Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18: 549-557, 2008.
76. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722, 2007.
77. Leeman RJ, Lui VW and Grandis JR: STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6: 231-241, 2006.
78. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
79. Achcar RO, Cagle PT and Jagirdar J: Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 131: 1350-1360, 2007.
80. Ma XT, Wang S, Ye YJ, Du RY, Cui ZR and Somsouk M: Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 10: 1569-1573, 2004.
81. Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, Chung AY, Jooi LL and Lee CG: Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53: 57-66, 2010.
82. Bronner C, Achour M, Arima Y, Chataigneau T, Saya H and Schini-Kerth VB: The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther 115: 419-434, 2007.
83. Robinson PA and Ardley HC: Ubiquitin-protein ligases. J Cell Sci 117: 5191-5194, 2004.
84. Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H and Saya H: Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9: 131-142, 2004.
85. He X, Duan C, Chen J, Ou-Yang X, Zhang Z, Li C and Peng H: Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett 583: 3501-3507, 2009.